The Finnish oral health innovation, Lumoral, will be presented at the upcoming Scandinavian Society of Periodontology (ScSP) Conference in Visby, Sweden, from August 22-25, 2024. This conference will focus on the latest developments in periodontal disease and treatments, with an emphasis on collaborative approaches in patient care.

At the event, key topics related to periodontology will be addressed, offering new insights for dental professionals, including specialists, general dentists, and dental hygienists. Koite Health Ltd, the Finnish health tech company behind Lumoral, will showcase how the antibacterial device is transforming preventive dental care across Europe and Asia.

About Lumoral

Lumoral is an oral health device utilizing dual light therapy, intended for use alongside regular tooth brushing. It is especially beneficial for individuals with periodontitis or those at risk for cavities, providing a scientifically proven antibacterial effect. Lumoral is a Class II medical device and CE-certified.

Conference Highlights

The ScSP Conference will feature a keynote from Professor Moritz Kebschull on advancements in periodontal classification and treatment guidelines. Professor Kajsa Henning Abrahamsson will present strategies for enhancing patient motivation, a critical component of effective periodontal care. The event will also spotlight young researchers, exploring topics like the connection between periodontal health and cognitive decline in dementia patients.

The second day will focus on regional trends in periodontal disease. Presentations by Associate Professors Shariel Sayardoust and Christian Damgaard will offer insights into the latest data from Sweden and Denmark, respectively. Additionally, Professor Charlota Pisinger will discuss the impact of new nicotine products on oral health and provide guidance for healthcare professionals in helping patients quit.

Lumoral’s Growing Research Base

Lumoral’s antibacterial technology has garnered academic interest, with 11 ongoing clinical studies across Finland, Sweden, Estonia, and Lithuania. These studies cover various topics, including periodontitis, peri-implantitis, and orthodontic care.

"We are honored to participate in the Scandinavian Society of Periodontology Conference, reinforcing our commitment to advancing periodontal care. We look forward to engaging with experts and sharing insights on how Lumoral can complement dental professionals’ efforts," said Mrs. Helen Huttunen, responsible for Lumoral sales in Sweden.

The Scandinavian Society of Periodontology

With over 150 members, the ScSP promotes the development of periodontology across the Nordic countries. It supports ongoing education and fosters collaboration among Scandinavian periodontists while maintaining traditional values.

The Finnish oral health innovation, Lumoral, has sparked significant interest in the academic community, with several new studies launching in recent months. Mikko Kylmänen, Research Manager at Koite Health Oy, provides updates on Lumoral's latest clinical research.

Currently, there are 11 ongoing clinical studies across Finland, Sweden, Estonia, and Lithuania investigating the Lumoral method. Five of these are funded by Koite Health Ltd, while the rest are conducted by independent academic research teams. The studies cover topics such as periodontitis, peri-implantitis, orthodontics, oral lichen planus, and the prevention of oral diseases in youth.

In 2024, two new academic research teams will start their Lumoral studies. One study will examine the impact of improved oral hygiene on managing and preventing periodontitis in patients with diabetes. Another study will focus on enhancing oral hygiene for elderly individuals living at home or receiving home care.

In Italy, two research groups are advancing their Lumoral studies: The University of Turin is investigating the prevention of oral mucositis symptoms caused by radiation therapy, and Sapienza University in Rome is studying methods to alleviate early symptoms of peri-implantitis. Additionally, Saveetha Dental College and Hospitals in Chennai, India, is planning to start a Lumoral study in 2024 focused on treating oral mucositis related to cancer therapies.

Research on oral mucositis is particularly significant, as no existing medication has successfully prevented its development. Mucositis, an inflammation of the oral mucosa associated with cancer treatments such as radiation and chemotherapy, causes severe pain, redness, and swelling, which can negatively impact the success of cancer treatment. Recent findings suggest that light-activated antibacterial therapy may be an effective way to manage this condition.

Recent Lumoral Studies Initiated in Early 2024:

1. HEALTHIER (Sweden): This study evaluates Lumoral's effectiveness in treating peri-implantitis and is conducted at the private Södertandläkarna clinic in Stockholm, Sweden, with 80 participants.
2. LumOsteo: This research examines Lumoral's role in preventing complications related to implant placement. It is being conducted at the Hammaslääkärit Eteläranta 10 clinic in Helsinki, Finland, with 40 participants.
3. Tartu University Plaque Study (Estonia): This crossover study compares two different oral hygiene methods and their effects on oral health. It is taking place at Tartu University in Estonia, where participants will alternate between using Lumoral and not using it to provide comparative results.

The HEALTHIER and LumOsteo studies are in their early stages, and precise timelines for results depend on factors such as patient recruitment. However, results from the Tartu plaque study are expected by the end of the year.

Summary of Previous Research Findings:

• Pilot Study on Peri-Implantitis (2022): Showed promising results in treating implant-related inflammations with Lumoral, including significant reductions in plaque and gum bleeding without side effects.
• Case Report on Periodontitis (2022): Demonstrated that Lumoral's antibacterial light treatment effectively eliminated harmful oral bacteria and improved severe periodontal disease outcomes.
• Clinical Randomized Study on Periodontitis (2022): Indicated significant improvements in periodontitis treatment outcomes when Lumoral was added to daily care.
• Clinical Randomized Study on Peri-Implantitis (2022): Observed reduced plaque, bleeding, and gum pocket sizes in Lumoral users compared to controls.
• Randomized Study on Oral Hygiene in Elderly Care (2023): Found that light-activated Lumoral treatment improved oral health and moisture in elderly individuals residing in 24-hour care facilities.
• Plaque Study in Healthy Adults (2023): Revealed that using Lumoral twice a week significantly reduced biofilm compared to a control group.

Innovation in Focus:

The ongoing and completed studies highlight Lumoral's versatile applications in improving oral health across various demographics and conditions. Mikko Kylmänen emphasizes that Lumoral's research opens new opportunities in oral care development. The company is proud to advance health and well-being through innovative solutions and looks forward to potential future applications of Lumoral.

For more information on Lumoral's research and effects, visit www.lumoralpro.com.

Finnish health technology company Koite Health Oy has signed a distribution agreement with Polish company HealthHub Pharma for its Lumoral oral health enhancing method. The partnership, which commenced in June 2024, will introduce the innovative Lumoral technology to the Polish market, which has around 40 million residents. The target audience includes health-conscious consumers, dental professionals, and dental clinics.

HealthHub Pharma is known for distributing and marketing innovative medical products in Poland. Wojciech Ślusarczyk, the company’s Business Development Manager, commented, "Lumoral is a valuable addition to our product range, marking our shift towards innovative and preventive dental therapies. The clinical background of Lumoral distinguishes it from other medical-grade dental products on the market."

Lumoral utilizes light-activated antibacterial technology to enhance oral hygiene and prevent oral diseases. Designed for home use, Lumoral helps reduce bacterial load in the mouth, slow plaque formation, and improve overall oral health. The product’s clinical validation ensures its effectiveness in maintaining oral health and preventing and treating common oral diseases such as gingivitis, periodontitis, and cavities.

Market Trends Support Lumoral Demand

According to Ślusarczyk, Poland's dental market is shifting towards preventive oral care, following the examples of Nordic countries and other Western nations, which could boost Lumoral’s sales.

"With 96% of the population suffering from tooth decay and up to 70% experiencing gum diseases, Lumoral has a significant opportunity. Our target groups include private dental practices, medical supply stores, wholesalers, and pharmacies. We are committed to excellent customer service and our customers can also order the Lumoral product directly from the www.lumoral.pl website."

Ślusarczyk outlined the company’s marketing strategy: "We are reaching out to dental practices, collaborating with wholesalers, and utilizing social media. Our marketing program, which includes offering free samples to clinics, is designed to gather feedback and build long-term relationships. We will also be participating in a number of notable dental trade fairs, including the prominent Krakdent fair that will take place in Kraków next April."

He added, "Although some professionals may be cautious about new technologies, we have not received negative feedback. We are also looking forward to the launch of Lumoral’s clinical device, which will enable its use as an adjunctive tool in dental practices. We strongly highlight six flagship indications of Lumoral (periodontitis, gingivitis, caries, orthodontics, implant health and halitosis, in which we would like to present our crucial supportive role of this medical device.”

Ślusarczyk also mentioned that Lumoral Junior, a version designed for children, will be available in the Polish market. Lumoral Junior is suitable for children aged 4–12, and children over 12 can switch to the adult Lumoral device. "We believe Lumoral Junior is a significant addition to the market and reflects our comprehensive approach to preventive dental care."

Broad Health Benefits of Lumoral

Ślusarczyk emphasized Lumoral's broader health benefits: "Oral health significantly impacts overall health, including diabetes management. Our goal is to enhance the understanding and prevention of oral diseases by providing innovative products like Lumoral."

The future of preventive dental care in Poland looks promising and Koite Health’s innovative Lumoral device addresses the needs of this evolving market, Ślusarczyk said.

Ślusarczyk explained: "Patient access to preventive care is likely to improve, potentially reducing the prevalence of oral diseases. This is crucial as over 96% of the population suffers from tooth decay."

Lumoral is user-friendly and designed for home use, fitting well with the growing trend of at-home preventive care. " Lumoral allows patients to take care of their own oral health and support dentists in their medical management, maintaining patients' good health during the treatment period," Ślusarczyk emphasized.

He also noted recent regulatory changes in Poland’s dental market, which could accelerate the shift towards preventive oral care by dental hygienists in Poland also creates opportunities for Lumoral. "Lumoral could be a valuable tool also for dental hygienists, helping them provide high-quality preventive care to their patients," Ślusarczyk noted.

"We are optimistic about Lumoral’s future in Poland, where the market is ripe for innovative solutions that can advance preventive care," Ślusarczyk concluded.

  "Our goal is to enhance the understanding and prevention of oral diseases by providing innovative products like Lumoral, " says Wojciech Ślusarczyk, Business Development Manager at HealthHub Pharma.